Literature DB >> 9918910

Quality of life before and after liver transplantation for cholestatic liver disease.

C R Gross1, M Malinchoc, W R Kim, R W Evans, R H Wiesner, J L Petz, J S Crippin, G B Klintmalm, M F Levy, P Ricci, T M Therneau, E R Dickson.   

Abstract

Liver transplantation (LT) is an established therapy for patients with end-stage primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC). In this report, we describe the health status and quality of life (QOL) in patients with these cholestatic liver diseases before and after LT. A QOL questionnaire was completed by 157 adult patients with PBC or PSC before and 1 year after liver transplantation at the Mayo Clinic or Baylor University Medical Center. This questionnaire measured four aspects of QOL, including symptoms; physical, social, and emotional functioning; health perceptions; and overall QOL. Changes in these QOL parameters before and after LT were described, and regression analysis was used to assess the relationships between clinical and QOL factors. There were no differences in QOL parameters between patients with PBC and PSC. QOL following transplantation was substantially better than before transplantation. This was observed in all four aspects of QOL. The degree of improvement as measured by effect size (difference in mean scores divided by the pretransplantation standard deviation) was 0.53 for symptoms (P <.01), 1.16 for function (P <.01), 2.37 for health satisfaction (P <.01), and 1.16 for overall QOL (P <.01). Patients' overall QOL before transplantation was significantly related to subjective and objective health status indicators and clinical factors such as ascites and renal dysfunction. QOL at 1-year follow-up, however, could not be adequately predicted by the pretransplantation subjective health status and clinical factors. Patients with end-stage cholestatic disease undergoing LT experience substantial improvement in all aspects of QOL addressed in this study. The patients' QOL 1 year after LT could not be predicted by pretransplantation variables used in this study.

Entities:  

Mesh:

Year:  1999        PMID: 9918910     DOI: 10.1002/hep.510290229

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

Review 1.  Primary biliary cirrhosis: new perspectives in diagnosis and treatment.

Authors:  M I Prince; D E Jones
Journal:  Postgrad Med J       Date:  2000-04       Impact factor: 2.401

Review 2.  Fatigue in cholestatic liver disease--a perplexing symptom.

Authors:  D Kumar; R K Tandon
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

3.  Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients.

Authors:  Francis S Lobo; Cynthia R Gross; Barbara J Matthees
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

Review 4.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 5.  Hepatic encephalopathy: a dynamic or static condition.

Authors:  Charmaine A Stewart; Jane Cerhan
Journal:  Metab Brain Dis       Date:  2005-09       Impact factor: 3.584

6.  Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis.

Authors:  A Jacoby; A Rannard; D Buck; N Bhala; J L Newton; O F W James; D E J Jones
Journal:  Gut       Date:  2005-06-16       Impact factor: 23.059

7.  Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost.

Authors:  Patrick G Northup; Michael M Abecassis; Michael J Englesbe; Jean C Emond; Vanessa D Lee; George J Stukenborg; Lan Tong; Carl L Berg
Journal:  Liver Transpl       Date:  2009-02       Impact factor: 5.799

8.  Effect of branched-chain amino acid supplementation on insulin resistance and quality of life in chronic hepatitis C patients.

Authors:  Alicia Ocaña-Mondragón; José Antonio Mata-Marín; Mario Uriarte-López; Carolina Bekker-Méndez; Enrique Alcalá-Martínez; Rosa María Ribas-Aparicio; Luis Antonio Uribe-Noguéz; Dulce María Rodríguez-Galindo; María de La Luz Martínez-Rodríguez
Journal:  Biomed Rep       Date:  2017-11-03

Review 9.  A review of quality of life instruments used in liver transplantation.

Authors:  Colleen L Jay; Zeeshan Butt; Daniela P Ladner; Anton I Skaro; Michael M Abecassis
Journal:  J Hepatol       Date:  2009-07-28       Impact factor: 25.083

Review 10.  Neuropsychological aspects of liver disease and its treatment.

Authors:  R E O'Carroll
Journal:  Neurochem Res       Date:  2007-10-24       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.